Abstract
Background Much of the early data on COVID-19 symptomatology was captured in the hospital setting. In a community setting the symptoms most predictive of SARS-CoV-2 positivity may be different. Data from the California sites of a COVID-19 community testing program are presented here.
Methods Prior to being tested, participants in the Baseline COVID-19 Testing Program completed an online screener, in which they self-reported basic demographics and the presence or absence of 10 symptoms. Both positive and negative COVID-19 RT-PCR tests were linked back to the screener data. A multivariable model of positivity was fit using generalized estimating equations, adjusting for month of testing as a fixed effect and accounting for clustering of data within each test site.
Results Among 547,018 first-time tests in California in 2020, positivity rates were 3.4%, 9.9%, and 19.8% for participants with no symptoms, 1 symptom, or 2 or more symptoms at the time of screening, respectively. All ten symptoms were individually associated with higher positivity rates, but only six of ten symptoms were associated with higher positivity when adjusting for other symptoms. Major symptoms with highest predictive value were recent loss of taste or smell, fever, and coughing with ORs of 3.27, 1.97, and 1.95, respectively. Shortness of breath and vomiting or diarrhea were negatively associated with positivity adjusting for other symptoms and, absent other symptoms, participants with these symptoms did not have significantly higher positivity rates than asymptomatic participants.
Conclusions Recent loss of taste and smell should be elevated to a major symptom along with fever and coughing in public health messaging and in our community approach to testing and surveillance, while mild to moderate shortness of breath should be de-emphasized as a sensitive early predictor of COVID-19 positivity.
Competing Interest Statement
DPM, RMC, RK, CS, JM and WJM own stock in Verily. JM is on the board of directors of Danaher.
Funding Statement
Verily Life Sciences receives funding from the state of California and from Rite Aid through its partnership with the U.S. Department of Health and Human Services (HHS) to support the operations of the community testing program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A written exemption was provided by WCG IRB, 1019 39th Ave, Suite 120, Puyallup, WA 98374 on March 3, 2021.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST: Verily Life Sciences receives funding from the state of California and from Rite Aid through its partnership with the U.S. Department of Health and Human Services (HHS) to support the operations of the community testing program. DPM, RMC, RK, CS, JM and WJM own stock in Verily. JM is on the board of directors of Danaher.
Data Availability
Data are only available in aggregate form, as presented in the paper. Due to the presence of protected health information (PHI), which is critical for meaningful analysis, in the form of test dates and county-level geographic identifiers, it is not possible to deidentify or anonymize the data to be shared beyond the presentation of aggregate data.
